Therapeutic Asset Ratings
395 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bpx-601
Prostate Cancer
Regeneron Pharmaceuticals
P1
C
(36)
Brodalumab
Prostate Cancer
Brian Henick, MD
P1
C
(36)
Cart-Psma Cells
Prostate Cancer
Nova Therapeutics LLC
P1
C
(36)
Cart-Psma-Tgfβrdn Cells
Prostate Cancer
University of Pennsylvania
P1
C
(36)
Clsp-1025
Prostate Cancer
Clasp Therapeutics, Inc.
P1
C
(36)
Dat-2645
Prostate Cancer
Danatlas Pharmaceuticals Co., Ltd
P1
C
(36)
Dntgfβrii-Armoured Steap2-Targeted Autologous Car T-Cell
Prostate Cancer
Shanghai AbelZeta Ltd.
P1
C
(36)
dxc008
Prostate Cancer
Hangzhou DAC Biotechnology Co., Ltd.
P1
C
(36)
dxc014
Prostate Cancer
Hangzhou DAC Biotechnology Co., Ltd.
P1
C
(36)
Ethiodized Oil
Prostate Cancer
University of California, San Francisco
P1
C
(36)
ETHYLICUM
Prostate Cancer
Icahn School of Medicine at Mount Sinai
P1
C
(36)
exs74539
Prostate Cancer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
C
(36)
flt3 ligand
Prostate Cancer
Ashutosh Kumar Tewari
P1
C
(36)
HRS-9815
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(36)
Ide-161
Prostate Cancer
IDEAYA Biosciences
P1
C
(36)
Idov-Immune
Prostate Cancer
ViroMissile, Inc.
P1
C
(36)
Ifosfamide
Prostate Cancer
Brigham and Women's Hospital
P1
C
(36)
Janx007
Prostate Cancer
Janux Therapeutics
P1
C
(36)
Janx014
Prostate Cancer
Janux Therapeutics
P1
C
(36)
LEVAMLODIPINE
Prostate Cancer
Tyler J Curiel
P1
C
(36)
ly4052031
Prostate Cancer
Eli Lilly and Company
P1
C
(36)
ly4101174
Prostate Cancer
Eli Lilly and Company
P1
C
(36)
Mdpk67B
Prostate Cancer
Med Discovery SA
P1
C
(36)
Micardis®
Prostate Cancer
Tyler J Curiel
P1
C
(36)
Moma-313
Prostate Cancer
MOMA Therapeutics
P1
C
(36)
Showing 301 to 325 of 395 assets
Previous
Page 13 of 16
Next